Aim
The aim of this work was to assess the risk of early fetal loss (first trimester of pregnancy, 8–13 weeks of gestation) using the results of first‐trimester screening (FTS) biochemical markers independently and combined.
Methods
FTS results of 152 women who suffered early fetal loss were compared to a control group of 150 women with normal pregnancy outcomes. FTS biochemical markers were measured with a Delfia Xpress 6000 analyzer and biochemical risks for Down's and Edward's syndromes were calculated using Prenatal‐Lifecycle version 3.0 software. Marker levels were standardized by calculating the gestational‐specific multiple of the medians (MoM), further adjusted by maternal age, maternal weight, cigarette consumption and pre‐existing type 1 diabetes mellitus. Receiver–operator curves were built to evaluate each marker and its combination.
Results
Our results show that values of biochemical risk of t21 of more than 1 in 310 have a poor sensitivity to predict early fetal loss (31.4%) with a positive predictive value (PPV) for fetal loss of 67.7%. Values of pregnancy‐associated plasma protein A (PAPP‐A) MoM of less than 0.48 show a sensitivity of 62.1% and a PPV of 84.5% for early fetal loss; whereas for free β‐human chorionic gonadotropin, values of MoM of less than 0.44 have a sensitivity of 66.4% with a PPV of 85.3%. A novel algorithm, consisting in the multiplication of both markers, shows for values of less than 0.48 a sensitivity of 83.1%, a specificity of 78.7% and a PPV of 77.1%.
Conclusion
Combined analysis of PAPP‐A and free β‐hCG appears to be a potential candidate to predict early fetal loss.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.